Patents by Inventor Antoine DECRULLE

Antoine DECRULLE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11970701
    Abstract: The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
    Type: Grant
    Filed: September 28, 2023
    Date of Patent: April 30, 2024
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Patent number: 11952595
    Abstract: The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
    Type: Grant
    Filed: July 7, 2023
    Date of Patent: April 9, 2024
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurelie Mathieu, Thibault Carlier
  • Patent number: 11952594
    Abstract: The present invention relates to the delivery of a payload by bacterial delivery vehicle, i.e. the encapsulation and the delivery of a single plasmid by different bacterial virus particles. More specifically, the present invention concerns a pharmaceutical composition comprising a payload packaged in at least two different bacterial delivery vehicles and a method of production thereof.
    Type: Grant
    Filed: August 19, 2021
    Date of Patent: April 9, 2024
    Assignee: ELIGO BIOSCIENCE
    Inventors: Antoine Decrulle, Xavier Duportet, Igor Stzepourginski
  • Patent number: 11946056
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Grant
    Filed: June 23, 2021
    Date of Patent: April 2, 2024
    Assignees: ELIGO BIOSCIENCE, INSTITUT PASTEUR
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Patent number: 11939598
    Abstract: The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
    Type: Grant
    Filed: May 18, 2023
    Date of Patent: March 26, 2024
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
  • Patent number: 11905516
    Abstract: The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than (100), preferably no more than (10), restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof.
    Type: Grant
    Filed: February 2, 2018
    Date of Patent: February 20, 2024
    Assignees: ELIGO BIOSCIENCE, INSTITUT PASTEUR
    Inventors: Antoine Decrulle, Jesus Fernandez Rodriguez, Xavier Duportet, David Bikard
  • Publication number: 20240043854
    Abstract: The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
    Type: Application
    Filed: September 28, 2023
    Publication date: February 8, 2024
    Inventors: Aymeric LEVEAU, Inès CANADAS BLASCO, Aurélie MATHIEU, Antoine DECRULLE
  • Publication number: 20240035038
    Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
    Type: Application
    Filed: September 29, 2023
    Publication date: February 1, 2024
    Inventors: Aymeric LEVEAU, Inès CANADAS BLASCO, Aurélie MATHIEU, Antoine DECRULLE
  • Publication number: 20240010994
    Abstract: The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
    Type: Application
    Filed: July 7, 2023
    Publication date: January 11, 2024
    Inventors: Jesus FERNANDEZ RODRIGUEZ, Antoine DECRULLE, Aymeric LEVEAU, Ines CANADAS BLASCO, Aurelie MATHIEU, Thibault CARLIER
  • Patent number: 11839645
    Abstract: The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
    Type: Grant
    Filed: December 8, 2022
    Date of Patent: December 12, 2023
    Assignee: Eligo Bioscience
    Inventors: Antoine Decrulle, Xavier Duportet
  • Patent number: 11840695
    Abstract: The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.
    Type: Grant
    Filed: August 24, 2022
    Date of Patent: December 12, 2023
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Patent number: 11820989
    Abstract: The invention relates to C. acnes carrying DNA vectors with a C. acnes phage packaging signal and a gene of interest. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a C. acnes phage packaging signal and a gene of interest, for the production of phage-derived particles that can robustly transduce C. acnes receiver cell allowing transgene expression. The invention encompasses C. acnes phage-derived particles carrying these vectors, C. acnes containing these vectors or modified by transduction of these phage-derived particles, and methods of using these phage-derived particles.
    Type: Grant
    Filed: November 4, 2021
    Date of Patent: November 21, 2023
    Assignee: Eligo Bioscience
    Inventors: Aymeric Leveau, Inès Canadas Blasco, Aurélie Mathieu, Antoine Decrulle
  • Publication number: 20230330157
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Application
    Filed: May 17, 2023
    Publication date: October 19, 2023
    Applicant: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Publication number: 20230279364
    Abstract: The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
    Type: Application
    Filed: May 18, 2023
    Publication date: September 7, 2023
    Inventors: Jesus FERNANDEZ RODRIGUEZ, Antoine DECRULLE, Aymeric LEVEAU, Ines CANADAS BLASCO, Aurélie MATHIEU, Thibault CARLIER
  • Patent number: 11739304
    Abstract: The present invention concerns a production bacterial cell for producing lytic phage particles or lytic phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural genes and at least one phage DNA packaging genes, said phage structural gene(s) and phage DNA packaging gene(s) being derived from a lytic bacteriophage, wherein the expression of at least one of said phage structural genes and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by an induction mechanism.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: August 29, 2023
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
  • Publication number: 20230218505
    Abstract: The present invention concerns a method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein said postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing said at least one bacteriocin and/or endolysin and wherein said postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
    Type: Application
    Filed: March 17, 2023
    Publication date: July 13, 2023
    Applicant: Eligo Bioscience
    Inventors: Antoine DECRULLE, Xavier DUPORTET
  • Patent number: 11697802
    Abstract: The present invention concerns a production bacterial cell for producing phage particles or phage-derived delivery vehicles, said production bacterial cell stably comprising at least one phage structural gene(s) and at least one phage DNA packaging gene(s), said phage structural gene(s) and phage DNA packaging gene(s) being derived from a first type of bacteriophage, wherein the expression of at least one of said phage structural gene(s) and/or at least one of said phage DNA packaging gene(s) in said production bacterial cell is controlled by at least one induction mechanism, and wherein said production bacterial cell is from a bacterial species or strain different from the bacterial species or strain from which said first type of bacteriophage comes and/or that said first type of bacteriophage targets.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: July 11, 2023
    Assignee: Eligo Bioscience
    Inventors: Jesus Fernandez Rodriguez, Antoine Decrulle, Aymeric Leveau, Ines Canadas Blasco, Aurélie Mathieu, Thibault Carlier
  • Publication number: 20230210961
    Abstract: The present invention concerns a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, preferably formulated, and a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin for use as a medicament, wherein said postbiotic is preferably a microbial lysate, preferably obtained from microorganisms heterologously expressing said at least one bacteriocin and/or endolysin and wherein said at least one postbiotic and said at least one bacteriocin and/or endolysin have a synergistic effect in the therapeutic treatment.
    Type: Application
    Filed: December 8, 2022
    Publication date: July 6, 2023
    Applicant: Eligo Bioscience
    Inventors: Antoine DECRULLE, Xavier DUPORTET
  • Patent number: 11690880
    Abstract: The invention encompasses compositions, kits and methods for modifying bacteria, preferably naturally occurring bacteria, in situ. These can be used to treat, prevent or cure microbiome-associated diseases or disorders by modulating the molecules expressed and/or secreted by bacterial populations of the microbiome in a specific manner. The genomic modifications can modify the interactions between part or all of these populations and the host in a way that decreases their deleterious potential on host health. The compositions, kits and methods of the invention do not result in the direct death of these populations or a direct significant inhibition of their growth. The invention further includes methods for screening for genetic modifications in the bacteria, for determining the efficiency of vectors at inducing these genetic mutations, and for determining the effects of these mutations on bacterial growth.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: July 4, 2023
    Assignee: Eligo Bioscience
    Inventors: Xavier Duportet, Antoine Decrulle, Cristina del Carmen Gil-Cruz, Christian Ivan Pérez-Shibayama, Burkhard Ludewig, Jesus Fernandez Rodriguez, Andreas Brodel
  • Patent number: 11633348
    Abstract: A method for the cosmetic caring of the skin and/or mucosa, comprising applying a postbiotic composition comprising at least one postbiotic and at least one bacteriocin and/or endolysin, wherein the postbiotic is preferably a bacterial lysate preferably obtained from bacteria heterologously expressing the at least one bacteriocin and/or endolysin and wherein the postbiotic and the at least one bacteriocin and/or endolysin have a synergistic effect in the cosmetic caring method.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: April 25, 2023
    Assignee: Eligo Bioscience
    Inventors: Antoine Decrulle, Xavier Duportet